shape-zoom2 shape-zoom2 chevron-down edit share2 twitter youtube

Feature

AMGEN’S GROWING IMMUNOTHERAPY ARSENAL

When it comes to enlisting the cancer-fighting potential of the body’s immune defenses, Amgen believes versatility is a virtue.

Explore the Feature

Feature

THE NEXT GENERATION OF BIOTECH MANUFACTURING

Amgen scientists are creating a new biomanufacturing paradigm that is leaner, greener, more flexible and productive and less costly to build and operate

Explore the Feature

Feature

GENETIC INSIGHTS FUEL ALZHEIMER'S BACE RACE

Amgen’s pursuit of Alzheimer’s treatments now includes a global collaboration with Novartis that focuses on the BACE gene, a target first cloned by Amgen and supported by genetic validation.

Explore the Feature

Feature

THE FUTURE OF BIOTECHNOLOGY

Just as advances in physics and engineering transformed life in the 20th century, rapid progress in biology is poised to change the world in the decades to come. Amgen R&D leader Sean Harper describes a rapid series of breakthroughs that clearly show that science has entered the Biocentury.

Explore the Feature

Feature

THE SHAPE OF DRUGS TO COME

Protein engineers are using the building blocks nature provides to design an ever-expanding toolkit of new drug modalities to fight disease.

Explore the Feature

Feature

PROBING NOVEL BIOLOGY

Amgen is using pioneering science to tackle drug targets where the genetic support is robust but the biology is mysterious.

Explore the Feature

Feature

A GENE LINKED TO LOWER RISK OF HEART ATTACKS

A rare mutation discovered at Amgen subsidiary deCODE Genetics is associated with a 34 percent lower risk of coronary artery disease. Amgen scientists aim to turn this insight into a new type of heart drug, which might complement lipid-lowering drugs by addressing other potential risk factors for heart disease.

Explore the Feature

Feature

BETTER SCIENCE THROUGH BIOSIMILAR R&D

Amgen helped to develop the science used in making biologic medicines, and we remain a leader in designing and manufacturing new biologics. This expertise is now being applied to the challenge of making high-quality biosimilars.

Explore the Feature

Resource

PARTNERING WITH AMGEN

Feature

THE ULTIMATE PARASITE

Amgen’s head of Discovery Research, Alexander Kamb, discusses his view on why we get cancer, what makes it so difficult to treat, and why immunotherapeutic approaches look so promising.

Explore the Feature

Feature

A PARAGON OF STRUCTURE-BASED DRUG DESIGN

While Amgen has long been recognized for its strength in developing biologic medicines, our expertise also extends to the field of small molecule drug design. The elegant science applied to a tough cancer target exemplifies this new capability.

Explore the Feature

About

About Amgen Science

Feature

THE PASSIONATE PURSUIT OF NAV 1.7

Recent research has shown that mutations in the gene for Nav 1.7, a sodium ion channel, can either ramp up pain or shut it down entirely. Amgen scientists are using creative approaches and unconventional tools to explore the potential of Nav 1.7 as a new drug target for pain.

Explore the Feature

Feature

THE NEW GENETICS